|
Novel Endoglycosidase Derivatives Treating Diseases of the Adaptive Immune System
Application
Protein-based therapeutics for the treatment of IgG-mediated diseases.
Key Benefits
A new class of endoglycosidases for the treatment of IgG-mediated diseases.
Four novel compounds have been developed that exhibited robust in vitro activity.
Potential to become first-in-class medications for dysregulation of the adaptive immune system,...
Published: 2/13/2025
Contributor(s): Eric Sundberg, Diego Sastre, Jonathan Du, Jeffrey Ravetch, Stylianos Bournazos
|
|
Functionalized Collagen Biochips with Core-Shell Structures and Collagen-Mimetic Peptide Nanotubes
Application
Synthetic collagen-based biomaterials for therapeutic delivery or drug testing.
Key Benefits
Synthetic collagen substitute.
Capable of formulating into various structures.
Free of animal-based contaminants.
Able to be spatially patterned.
Market Summary
Organ failure and tissue defects affect millions of Americans, resulting in...
Published: 2/13/2025
Contributor(s): Vincent Conticello, Andrea Merg, Gavin Touponse
|
|
KRAS Mutant Protein-Protein Interaction Targets and Inhibitors for Cancer Therapy
Application
Immunotherapeutic agent and biosensor for KRASG12V mutation in tumor cells.
Key Benefits
First in class, targeted immunotherapy for patients presented with KRASG12V mutation.
Attenuates immune suppression associated with KRASG12V-positive cancers.
Market Summary
The KRASG12V mutation, representing 85% of all cancer mutations, is...
Published: 2/13/2025
Contributor(s): Haian Fu, Cong Tang, Xiulei Mo
|
|
Caspase-3 Deficient MEFs with Mutant Caspase-3 Re-Introduced
Application
Mouse embryonic fibroblast (MEF) line deficient in caspase-3 that are reconstituted with constitutively expressed mutant versions of the protease.
Key Benefits
An immortalized caspase-3-deficient MEF cell line.
Tool to study protease induced apoptosis.
Technical Summary
Emory inventors have discriminated a previously unknown role...
Published: 2/13/2025
Contributor(s): Lawrence Boise, Katelyn Ponder
|
|
Ribosome Pegging: An Antibiotic-free System to Produce Recombinant Proteins
Application
Antibiotic-free method to prevent the growth of cells that fail to express high levels of a non-essential protein (target protein).
Key Benefits
Prevents the use of antibiotics and markers that promote resistance.
Facilitates the deployment of recombinant bacteria in uncontrolled environments.
Stabilizes heterologous expression of...
Published: 2/13/2025
Contributor(s): Ichiro Matsumura
|
|
Selective Enrichment of A-To-I Edited Transcripts from Cellular RNA Using Endonuclease V
Application
Kit to efficiently identify and enrich adenosine-to-inosine (A-to-I) editing in RNA molecules.
Key Benefits
Robust and facile method for enriching A-to-I edited transcripts.
Overcomes the low efficiency and accuracy of transcriptome-wide RNA-seq.
Market Summary
A-to-I RNA editing by adenosine deaminases is a common RNA modification...
Published: 2/13/2025
Contributor(s): Steven Knutson, Jennifer Heemstra
|
|
Cas9 Controlled Gene Activation
Application
Flexible system using Cas9 to modulate gene expression.
Key Benefits
Edits genes by cleaving DNA as well as inhibiting transcription.
No need to transfect cells with additional Cas9.
Market Summary
The CRISPR-Cas9 system is a bacterial adaptive immune system that has been appropriated for genetic engineering. The CRISPR-Cas9 system...
Published: 2/13/2025
Contributor(s): David Weiss, Hannah Ratner
|
|
DNAzyme Nanoparticles for the Cleavage of RNA
Application
Site-selective RNA splicing nanozyme for cleaving and ligating RNA.
Key Benefits
Can cleave virtually any RNA stem loop.
Removes a 19 nucleotide segment from a 67 nucleotide RNA loop with up to 66% efficiency.
Technical Summary
Modulating RNA can be useful for studying RNA biology, gene knockdown, and regulating RNA splicing. Scientists...
Published: 2/13/2025
Contributor(s): Jessica Petree, Kevin Yehl, Khalid Salaita
|
|
Trimeric Immunogen for HIV-1 Vaccination
Application
Trimeric gp120 immunogen that induces broadly cross-reactive V1V2-antibodies for HIV-1 vaccine.
Key Benefits
Possible oral administration.
Broadly cross-reactive against HIV-1 panel.
Promotes antibody responses as both a primary immunogen and boosting immunogen.
Market Summary
Antiretroviral therapy (ART) has dramatically prolonged...
Published: 2/13/2025
Contributor(s): Rama Rao Amara, Andrew Jones, Raghavan Varadarajan, Sannula Kesavardhana
|
|
IFN Gamma Prelicensing for Improved Mesenchymal Stromal Cell Function Post-Thaw
Application
Mesenchymal stromal cells (MSC) prelicensed with pro-inflammatory cytokines for improved survival and immunosuppressive properties following cryopreservation.
Key Benefits
Preserves the immunosuppressive function of MSCs following thawing.
Improves effectiveness of transplanted MSCs following cryopreservation.
Market Summary
Mesenchymal...
Published: 2/13/2025
Contributor(s): Jacques Galipeau, Raghavan Chinnadurai
|
